2023
384 Vaso-Occlusive Pain Requiring Hospitalization or Treatment Is Rare Following Successful Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L, He Z, Deng Y, Hamidi R, Flagg A, Shah N. 384 Vaso-Occlusive Pain Requiring Hospitalization or Treatment Is Rare Following Successful Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s291. DOI: 10.1016/s2666-6367(23)00453-0.Peer-Reviewed Original Research488 Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study
Khemani K, Stenger E, Arnold S, Bakshi N, Ross D, Smith C, Basu A, Krishnamurti L. 488 Feasibility of Using the American Time Use Survey to Study the Impact of Sickle Cell Disease and Hematopoietic Cell Transplant on the Daily Lives of Patients and Their Caregivers: A Stellar Study. Transplantation And Cellular Therapy 2023, 29: s366. DOI: 10.1016/s2666-6367(23)00556-0.Peer-Reviewed Original ResearchThrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin
Chiang K, Gupta A, Sundd P, Krishnamurti L. Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. Biomedicines 2023, 11: 338. PMID: 36830874, PMCID: PMC9953430, DOI: 10.3390/biomedicines11020338.Peer-Reviewed Original ResearchSickle cell diseaseVaso-occlusive crisisCell diseaseLipid mediatorsCOVID-19Severe SARS-CoV-2 infectionSARS-CoV-2 infectionSevere COVID-19Platelet-leukocyte adhesionAnti-thrombotic agentsThrombo-InflammationEndothelial injuryRespiratory infectionsSevere illnessClinical trialsThromboxane ATherapeutic strategiesTherapeutic targetPotential treatmentPlatelet activationComplement activationGreater riskClinical researchDiseaseEndothelial cells
2022
Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study
George S, Veludhandi A, Xiang Y, Stenger E, Arnold S, Mehta A, Schirmer D, Spencer J, Guilcher G, Bhatia M, Abraham A, Gomez-Lobo V, Krishnamurti L, Meacham L. Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study. Blood 2022, 140: 1391-1392. DOI: 10.1182/blood-2022-168060.Peer-Reviewed Original ResearchPreliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study
Meacham L, Veludhandi A, Xiang Y, Stenger E, Arnold S, Mehta A, Pecker L, Hsieh M, Maher J, Krishnamurti L. Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study. Blood 2022, 140: 1397-1398. DOI: 10.1182/blood-2022-163279.Peer-Reviewed Original ResearchEffects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study [Erratum]
Rodgers-Melnick S, Lin L, Gam K, Souza de Santana Carvalho E, Jenerette C, Rowland D, Little J, Dusek J, Bakshi N, Krishnamurti L. Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study [Erratum]. Journal Of Pain Research 2022, 15: 1123-1124. PMID: 35469252, PMCID: PMC9034844, DOI: 10.2147/jpr.s370799.Peer-Reviewed Original Research21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy
Schoettler M, Spencer K, Lutterman D, Rumbika S, Haight A, Stenger E, Parikh S, Qayed M, Watkins B, Krishnamurti L, Williams K, Chonat S. 21 Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy. Transplantation And Cellular Therapy 2022, 28: s20-s21. DOI: 10.1016/s2666-6367(22)00182-8.Peer-Reviewed Original Research58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study
Stenger E, Chellapandian D, Shah R, Gillepsie S, Xiang Y, Bhatia M, Chaudhury S, Eckrich M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Olson T, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A. 58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study. Transplantation And Cellular Therapy 2022, 28: s49-s51. DOI: 10.1016/s2666-6367(22)00219-6.Peer-Reviewed Original Research
2021
Gaps in Medicaid Coverage and Financial Toxicity: A Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L. Gaps in Medicaid Coverage and Financial Toxicity: A Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 27: 284-285. PMID: 33836866, DOI: 10.1016/j.jtct.2021.03.016.Peer-Reviewed Original Research363 Hematopoietic Cell Transplant Outcomes Among Medicaid and Privately Insured Patients with Sickle Cell Disease
Mupfudze T, Meyer C, Krishnamurti L, Preussler J, Mau L, Bolon Y, Steinert P, Arnold S, Saber W. 363 Hematopoietic Cell Transplant Outcomes Among Medicaid and Privately Insured Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 27: s306. DOI: 10.1016/s2666-6367(21)00389-4.Peer-Reviewed Original Research386 Cryptogenic Organizing Pneumonia Following HLA Identical Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: A Case Series of Three Pediatric Patients
Bauchat A, Williams K, Simon D, Parikh S, Krishnamurti L. 386 Cryptogenic Organizing Pneumonia Following HLA Identical Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: A Case Series of Three Pediatric Patients. Transplantation And Cellular Therapy 2021, 27: s321-s322. DOI: 10.1016/s2666-6367(21)00412-7.Peer-Reviewed Original Research
2020
Educational needs of patients and caregivers living with sickle cell disease results in development of web‐based patient decision aid
Ross D, Sinha C, Bakshi N, Krishnamurti L. Educational needs of patients and caregivers living with sickle cell disease results in development of web‐based patient decision aid. Journal Of Advanced Nursing 2020, 77: 1432-1441. PMID: 33277763, DOI: 10.1111/jan.14704.Peer-Reviewed Original ResearchConceptsSickle cell diseasePatients/caregiversWeb-based patient decision aidQuality of lifeTreatment optionsCell diseasePatient decision aidWeb-based decision aidPotential treatment optionHealthcare provider educationInitial needs assessmentDecision aidAdult patientsAvailable therapiesProvider educationSemi-structured qualitative interviewsPatientsHealthcare providersWay patientsDecisional needsInternet-based searchDiseaseCaregiversFurther recruitmentNeeds assessmentShould young children with sickle cell disease and an available human leukocyte antigen identical sibling donor be offered hematopoietic cell transplantation?
Krishnamurti L. Should young children with sickle cell disease and an available human leukocyte antigen identical sibling donor be offered hematopoietic cell transplantation? Hematology/Oncology And Stem Cell Therapy 2020, 13: 53-57. PMID: 32202246, DOI: 10.1016/j.hemonc.2019.12.008.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseaseQuality of lifeOverall survivalCell transplantationCell diseaseYoung childrenHLA-identical siblingsHuman leukocyte antigenSevere clinical presentationAvailable human leukocyte antigenFree survivalOrgan dysfunctionClinical presentationLeukocyte antigenIdentical siblingsPremature mortalityAvailable HLAYounger ageTransplantationHLAAgeDiseaseChildrenSurvivalPrevalence and predictors of chronic pain intensity and disability among adults with sickle cell disease
Matthie N, Jenerette C, Gibson A, Paul S, Higgins M, Krishnamurti L. Prevalence and predictors of chronic pain intensity and disability among adults with sickle cell disease. Health Psychology Open 2020, 7: 2055102920917250. PMID: 32426150, PMCID: PMC7218472, DOI: 10.1177/2055102920917250.Peer-Reviewed Original ResearchChronic pain intensitySickle cell diseasePain intensityCell diseaseChronic painConsistent clinical assessmentPalliative care approachChronic pain impactMiddle-aged adultsPain impactPain catastrophizingClinical assessmentCare approachPsychosocial healthDisability prevalencePsychosocial predictorsYoung womenDiseaseMost participantsDisabilityPainAdultsCatastrophizingPrevalenceAge
2019
How I treat sickle cell disease with hematopoietic cell transplantation
Stenger E, Shenoy S, Krishnamurti L. How I treat sickle cell disease with hematopoietic cell transplantation. Blood 2019, 134: 2249-2260. PMID: 31697818, PMCID: PMC6923666, DOI: 10.1182/blood.2019000821.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseaseCell transplantationCell diseaseOrgan dysfunctionSCD patientsSignificant morbidityEarly mortalityClinical trialsAvailable cureSCD recipientsAlternative donorsIndividual patientsClinical practicePatientsTransplantationClinical vignettesDiseaseOutcomesMorbidityDysfunctionMortalityTrialsRecipients
2018
Ovarian Sertoli–Leydig tumor after bone marrow transplant for sickle cell disease
Phillips L, Krishnamurti L, Rytting H, Olson T. Ovarian Sertoli–Leydig tumor after bone marrow transplant for sickle cell disease. Pediatric Blood & Cancer 2018, 65: e27367. PMID: 30039911, DOI: 10.1002/pbc.27367.Peer-Reviewed Original ResearchFrom trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea
Sinha C, Bakshi N, Ross D, Krishnamurti L. From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. PLOS ONE 2018, 13: e0199375. PMID: 29949647, PMCID: PMC6021071, DOI: 10.1371/journal.pone.0199375.Peer-Reviewed Original ResearchConceptsSickle cell diseaseGroup 1 participantsGroup 2 participantsCell diseaseSide effectsAdult SCD patientsPatient-related factorsPotential side effectsAdult patientsSCD patientsHU usePatients' attitudesAge 31Age groupsAge 18PatientsYoung adultsEfficacySignificant differencesAdultsEffective alternativeDiseaseRiskParticipantsQualitative interviewsSickle cell disease
Kato G, Piel F, Reid C, Gaston M, Ohene-Frempong K, Krishnamurti L, Smith W, Panepinto J, Weatherall D, Costa F, Vichinsky E. Sickle cell disease. Nature Reviews Disease Primers 2018, 4: 18010. PMID: 29542687, DOI: 10.1038/nrdp.2018.10.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCell diseaseHaematopoietic stem cell transplantationAcute pain eventsAcute chest syndromeHigh-burden settingsStem cell transplantationCommon acute complicationHemoglobin subunit βNewborn screening programsUniversal newborn screening (NBS) programsChest syndromeAcute complicationsChronic complicationsBlood transfusionCell transplantationPathophysiological mechanismsPain eventsScreening programEarly diagnosisSCD phenotypeImmune systemΒ-globin subunitDiseaseComplicationsAssociation of genetic variation in COMT gene with pain related to sickle cell disease in patients from the walk-PHaSST study
Zhang Y, Belfer I, Nouraie M, Zeng Q, Goel R, Chu Y, Krasiy I, Krishnamurti L. Association of genetic variation in COMT gene with pain related to sickle cell disease in patients from the walk-PHaSST study. Journal Of Pain Research 2018, 11: 537-543. PMID: 29559808, PMCID: PMC5856032, DOI: 10.2147/jpr.s149958.Peer-Reviewed Original ResearchVaso-occlusive pain episodesSickle cell diseasePain perceptionSCD patientsCell diseaseAfrican American SCD patientsVariability of painEmergency room visitsHealth care utilizationSelf-reported painPain episodesAcute painCare utilizationRoom visitsSS patientsFunctional variantsPainPatientsPsychological covariatesDisease biologyCOMT geneDiseaseRisk SNPsWomenCorresponding haplotypes
2017
Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module
Panepinto J, Paul Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Charles Casper T, Cook L, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Brousseau D, for the Pediatric Emergency Care Applied Research Network (PECARN). Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module. Health And Quality Of Life Outcomes 2017, 15: 124. PMID: 28606098, PMCID: PMC5468970, DOI: 10.1186/s12955-017-0700-2.Peer-Reviewed Original ResearchConceptsSickle Cell Disease ModuleDisease-specific HRQL instrumentsHealth-related qualityPatient-centered outcomesProspective trial designSickle cell diseaseSpecific HRQL instrumentsHRQL assessmentHRQL instrumentsLongitudinal validityAncillary studiesCell diseaseTrial designHealth statusDisease modulesTime pointsPedsQLMeaningful changeChildrenHRQLPatientsHospitalDisease